000756 新华制药
已收盘 04-17 15:00:00
资讯
新帖
简况
新华制药(000756.SZ)取得布美他尼注射液药品注册证书
智通财经 · 04-15 16:50
新华制药(000756.SZ)取得布美他尼注射液药品注册证书
新华制药：醋酸可的松滴眼液主要用于过敏性眼病
证券之星 · 04-09
新华制药：醋酸可的松滴眼液主要用于过敏性眼病
新华制药：有关治疗阿尔茨海默病的创新药OAB-14进展情况，请关注巨潮资讯网公司刊载的公告
证券之星 · 04-09
新华制药：有关治疗阿尔茨海默病的创新药OAB-14进展情况，请关注巨潮资讯网公司刊载的公告
新华制药获注射用浓钠钾镁钙溶液药品注册证书
美股速递 · 04-07
新华制药获注射用浓钠钾镁钙溶液药品注册证书
新华制药（000756）披露获得钠钾镁钙注射用浓溶液药品注册证书，4月7日股价上涨1.36%
证券之星 · 04-07
新华制药（000756）披露获得钠钾镁钙注射用浓溶液药品注册证书，4月7日股价上涨1.36%
新华制药(000756.SZ)获钠钾镁钙注射用浓溶液药品注册证书
智通财经 · 04-03
新华制药(000756.SZ)获钠钾镁钙注射用浓溶液药品注册证书
市占率第一、营收1亿：光芯片独角兽曦智科技带着“冰与火”赴港递表
华尔街见闻 · 04-02
市占率第一、营收1亿：光芯片独角兽曦智科技带着“冰与火”赴港递表
新华制药最新公告：获得《药品补充申请批准通知书》
证券之星 · 04-01
新华制药最新公告：获得《药品补充申请批准通知书》
新华制药牛黄甲硝唑胶囊补充申请获国家药监局批准
美股速递 · 04-01
新华制药牛黄甲硝唑胶囊补充申请获国家药监局批准
新华制药：董事会审议通过《关于2025年度报告及业绩公告的议案》等多项议案
证券日报 · 03-29
新华制药：董事会审议通过《关于2025年度报告及业绩公告的议案》等多项议案
新华制药(000756)2月28日股东户数7.69万户，较上期减少0.71%
证券之星 · 03-29
新华制药(000756)2月28日股东户数7.69万户，较上期减少0.71%
新华制药(000756.SZ)发布2025年度业绩，归母净利润2.9亿元，同比下降38.32%
智通财经 · 03-29
新华制药(000756.SZ)发布2025年度业绩，归母净利润2.9亿元，同比下降38.32%
股市必读：新华制药（000756）3月23日收盘跌5.23%，主力净流出1938.92万元
证券之星 · 03-24
股市必读：新华制药（000756）3月23日收盘跌5.23%，主力净流出1938.92万元
新华制药(000756.SZ)子公司获布洛芬颗粒药品注册证
智通财经 · 03-23
新华制药(000756.SZ)子公司获布洛芬颗粒药品注册证
新华制药最新公告：获得依折麦布片上市许可持有人变更批准
证券之星 · 03-16
新华制药最新公告：获得依折麦布片上市许可持有人变更批准
新华制药依折麦布片变更上市许可持有人获批准
美股速递 · 03-16
新华制药依折麦布片变更上市许可持有人获批准
新华制药：公司构建创新药+特色原料药+高端制剂+CDMO立体布局
证券日报 · 03-09
新华制药：公司构建创新药+特色原料药+高端制剂+CDMO立体布局
新华制药(000756.SZ)子公司获沙格列汀二甲双胍缓释片药品注册证书
智通财经 · 03-04
新华制药(000756.SZ)子公司获沙格列汀二甲双胍缓释片药品注册证书
新华制药(000756.SZ)获恩他卡朋片药品注册证
智通财经 · 03-04
新华制药(000756.SZ)获恩他卡朋片药品注册证
新华制药沙格列汀与盐酸二甲双胍缓释片获批药品注册证书
美股速递 · 03-04
新华制药沙格列汀与盐酸二甲双胍缓释片获批药品注册证书
公司概况
公司名称：
山东新华制药股份有限公司
所属行业：
医药制造业
上市日期：
1997-08-06
主营业务：
山东新华制药股份有限公司的主营业务是开发、制造和销售化学原料药、制剂及化工产品。公司的主要产品是解热镇痛类等原料药、片剂、针剂、胶囊剂等制剂、医药中间体及其他。
发行价格：
3.45
{"stockData":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"新华制药","latestPrice":14.61,"timestamp":1776409401000,"preClose":14.76,"halted":0,"volume":4367937,"delay":0,"changeRate":-0.0102,"floatShares":499000000,"shares":697000000,"eps":0.1576,"marketStatus":"已收盘","change":-0.15,"latestTime":"04-17 15:00:00","open":14.67,"high":14.75,"low":14.53,"amount":63764800,"amplitude":0.0149,"askPrice":14.61,"askSize":4,"bidPrice":14.6,"bidSize":685,"shortable":0,"etf":0,"ttmEps":0.1576,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":5,"adr":0,"adjPreClose":14.76,"symbolType":"stock","openAndCloseTimeList":[[1776389400000,1776396600000],[1776402000000,1776409200000]],"highLimit":16.24,"lowLimit":13.28,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":696683435,"isCdr":false,"pbRate":1.97,"roa":"--","peRate":92.703046,"roe":"5.66%","epsLYR":0.42,"committee":0.362969,"marketValue":10179000000,"turnoverRate":0.0088,"status":1,"hkstockBrief":{"symbol":"00719","market":"HK","secType":"STK","nameCN":"山东新华制药股份","latestPrice":6.37,"timestamp":1776408597935,"preClose":6.44,"halted":0,"volume":254000,"delay":0,"premium":"-61.97"},"floatMarketCap":7289000000},"requestUrl":"/m/hq/s/000756/wiki","defaultTab":"wiki","newsList":[{"id":"2627402263","title":"新华制药(000756.SZ)取得布美他尼注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2627402263","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627402263?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:50","pubTimestamp":1776243047,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药 公告，公司收到国家药品监督管理局核准签发的布美他尼注射液《药品注册证书》。在高血压的梯度疗法中，不作为治疗原发性高血压的首选药物，但当噻嗪类药物疗效不佳，尤其当伴有肾功能不全或出现高血压危象时，本类药物尤为适用。抗利尿激素分泌过多症。急性药物毒物中毒等的治疗，如巴比妥类药物中毒等。对某些呋塞米无效的病例仍可能有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新华制药(000756.SZ)取得布美他尼注射液药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0164","BK0239","000756"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626298902","title":"新华制药：醋酸可的松滴眼液主要用于过敏性眼病","url":"https://stock-news.laohu8.com/highlight/detail?id=2626298902","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626298902?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:33","pubTimestamp":1775723589,"startTime":"0","endTime":"0","summary":"证券之星消息，新华制药04月09日在投资者关系平台上答复投资者关心的问题。醋酸可的松滴眼液主要用于过敏性眼病，属于糖皮质激素类眼药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900026018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","000756","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902334","title":"新华制药：有关治疗阿尔茨海默病的创新药OAB-14进展情况，请关注巨潮资讯网公司刊载的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902334","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626902334?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:12","pubTimestamp":1775722325,"startTime":"0","endTime":"0","summary":"证券之星消息，新华制药04月09日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好：新华制药研发用于治疗阿尔茨海默病的创新药OAB-14，之前公告已经进入二期临床实验了，距离上次公示已经一年了，这款药物进展如何了，是不是今年能上市？巨潮资讯网是公司指定信息披露媒体，有关治疗阿尔茨海默病的创新药OAB-14进展情况，请关注巨潮资讯网公司刊载的公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900024773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","000756","BK0239","159992","06978","BK1574","BK0164"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133210206","title":"新华制药获注射用浓钠钾镁钙溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1133210206","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133210206?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:38","pubTimestamp":1775558308,"startTime":"0","endTime":"0","summary":"新华制药近日成功获得国家药品监督管理局核准签发的注射用浓钠钾镁钙溶液药品注册证书。这一重要进展标志着该公司在电解质补充剂领域的产品线得到进一步拓展与强化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0164","000756","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625312219","title":"新华制药（000756）披露获得钠钾镁钙注射用浓溶液药品注册证书，4月7日股价上涨1.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625312219","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625312219?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:17","pubTimestamp":1775557033,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘，新华制药报收于14.92元，较前一交易日上涨1.36%，最新总市值为103.95亿元。该股当日开盘14.88元，最高14.92元，最低14.52元，成交额达8201.42万元，换手率为1.11%。近日，山东新华制药股份有限公司收到国家药品监督管理局核准签发的钠钾镁钙注射用浓溶液《药品注册证书》，药品批准文号为国药准字H20263780，剂型为注射剂，规格20ml，注册分类为化学药品3类。公司于2026年1月递交上市许可申请并获受理，同年4月获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700025261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0239","BK0164"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624659134","title":"新华制药(000756.SZ)获钠钾镁钙注射用浓溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2624659134","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624659134?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:41","pubTimestamp":1775209263,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)公告，公司收到国家药品监督管理局核准签发的钠钾镁钙注射用浓溶液《药品注册证书》。本品用于通过中心静脉输注含浓葡萄糖或氨基酸的溶液时的电解质补充，以维持成人患者的电解质动态平衡","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000756","BK0164","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624579462","title":"市占率第一、营收1亿：光芯片独角兽曦智科技带着“冰与火”赴港递表","url":"https://stock-news.laohu8.com/highlight/detail?id=2624579462","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624579462?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:06","pubTimestamp":1775117205,"startTime":"0","endTime":"0","summary":"相信光的力量？","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3769090","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","NVDA","00700","COHR","09888","000756","00719","BK4588","BK4585","LITE","BIDU","TCEHY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2624151081","title":"新华制药最新公告：获得《药品补充申请批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2624151081","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624151081?lang=zh_cn&edition=full","pubTime":"2026-04-01 23:50","pubTimestamp":1775058649,"startTime":"0","endTime":"0","summary":"新华制药(000756.SZ)公告称，公司近日收到国家药品监督管理局核准签发的人工牛黄甲硝唑胶囊《药品补充申请批准通知书》，批准本品上市许可持有人转让补充申请。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100043106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0239","BK0164"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112736876","title":"新华制药牛黄甲硝唑胶囊补充申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1112736876","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112736876?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:38","pubTimestamp":1775032692,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司（股票代码：000756）近日宣布，其牛黄甲硝唑胶囊的补充药品注册申请已获得国家药品监督管理局（NMPA）正式批准。\n此次获批标志着该产品在临床应用范围或生产工艺优化等方面取得新的进展，有望为患者提供更安全、有效的治疗选择，同时也将进一步提升新华制药在消化系统及抗感染药物市场的竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0164","000756","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623635936","title":"新华制药：董事会审议通过《关于2025年度报告及业绩公告的议案》等多项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2623635936","media":"证券日报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623635936?lang=zh_cn&edition=full","pubTime":"2026-03-29 20:15","pubTimestamp":1774786500,"startTime":"0","endTime":"0","summary":"证券日报网讯3月29日，新华制药发布公告称，公司第十一届董事会第十次会议审议通过《关于2025年度报告及业绩公告的议案》《关于2025年度利润分配的议案》《关于续聘会计师事务所的议案》等多项议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603293688038165.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0164","000756"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623358004","title":"新华制药(000756)2月28日股东户数7.69万户，较上期减少0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623358004","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623358004?lang=zh_cn&edition=full","pubTime":"2026-03-29 17:02","pubTimestamp":1774774943,"startTime":"0","endTime":"0","summary":"证券之星消息，近日新华制药披露，截至2026年2月28日公司股东户数为7.69万户，较12月31日减少550.0户，减幅为0.71%。在化学制药行业个股中，新华制药股东户数高于行业平均水平，截至2月28日，化学制药行业平均股东户数为3.44万户。从股价来看，2025年12月31日至2026年2月28日，新华制药区间涨幅为3.05%，在此期间股东户数减少550.0户，减幅为0.71%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900007905.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","BK0239","000756"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623935817","title":"新华制药(000756.SZ)发布2025年度业绩，归母净利润2.9亿元，同比下降38.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623935817","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623935817?lang=zh_cn&edition=full","pubTime":"2026-03-29 16:36","pubTimestamp":1774773386,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)披露2025年年度报告，报告期公司实现营收87.55亿元，同比增长3.41%;归母净利润2.9亿元，同比下降38.32%;扣非净利润2.68亿元，同比下降40.10%;基本每股收益0.42元。公司拟向全体股东派发2025年末期股息每股人民币0.15元(含税)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"新华制药(000756.SZ)发布2025年度业绩，归母净利润2.9亿元，同比下降38.32%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000756"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621085869","title":"股市必读：新华制药（000756）3月23日收盘跌5.23%，主力净流出1938.92万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621085869","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621085869?lang=zh_cn&edition=full","pubTime":"2026-03-24 01:43","pubTimestamp":1774287791,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，新华制药报收于13.96元，下跌5.23%，换手率1.8%，成交量9.0万手，成交额1.27亿元。当日关注点来自交易信息汇总：新华制药股价连续5日下跌，3月23日收盘跌5.23%，主力资金当日净流出1938.92万元。前10个交易日主力资金累计净流出9175.79万元，股价累计下跌8.91%；融资余额累计减少1165.87万元，融券余量累计减少1.11万股。本次获批进一步丰富公司布洛芬产品剂型，但药品销售受政策和市场因素影响存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400001661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0164","000756"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621877984","title":"新华制药(000756.SZ)子公司获布洛芬颗粒药品注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2621877984","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621877984?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:58","pubTimestamp":1774256281,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)公告，公司全资子公司山东淄博新达制药有限公司(简称“新达制药”)收到国家药品监督管理局核准签发的布洛芬颗粒《药品注册证书》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0164","000756"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619518024","title":"新华制药最新公告：获得依折麦布片上市许可持有人变更批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619518024","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619518024?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:00","pubTimestamp":1773655203,"startTime":"0","endTime":"0","summary":"新华制药(000756.SZ)公告称，公司收到国家药品监督管理局核准签发的依折麦布片《药品补充申请批准通知书》，批准本品上市许可持有人转让补充申请。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600026281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0164","000756"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164703743","title":"新华制药依折麦布片变更上市许可持有人获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1164703743","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164703743?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:37","pubTimestamp":1773653830,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司近日宣布，其生产的依折麦布片变更上市许可持有人的申请已获得相关监管部门的批准。此次变更将有助于公司优化产品管理结构，提升市场运营效率。依折麦布片作为一种重要的降血脂药物，其上市许可持有人的变更不会影响产品的质量和市场供应，公司将继续确保该药品的安全性和有效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0164","BK0239","000756"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618259096","title":"新华制药：公司构建创新药+特色原料药+高端制剂+CDMO立体布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2618259096","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618259096?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:10","pubTimestamp":1773058240,"startTime":"0","endTime":"0","summary":"证券日报网讯3月9日，新华制药在互动平台回答投资者提问时表示，公司以大研发+全产业链+国际化为核心，构建创新药+特色原料药+高端制剂+CDMO的立体布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666266727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","06978","BK0239","BK1161","159992","BK0164","CDMO","BK1574","000756"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616389205","title":"新华制药(000756.SZ)子公司获沙格列汀二甲双胍缓释片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616389205","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616389205?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:56","pubTimestamp":1772614570,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)公告，公司全资子公司山东淄博新达制药有限公司(简称“新达制药”)收到国家药品监督管理局核准签发的沙格列汀二甲双胍缓释片(Ⅰ)、(Ⅲ)《药品注册证书》。本品配合饮食和运动治疗，适合使用沙格列汀和二甲双胍治疗的2型糖尿病成人患者，以改善此类患者的血糖控制。本品不用于1型糖尿病或糖尿病酮症酸中毒的患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000756","BK0239","BK0164"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616953896","title":"新华制药(000756.SZ)获恩他卡朋片药品注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2616953896","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616953896?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:49","pubTimestamp":1772614182,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)公告，公告收到国家药品监督管理局核准签发的恩他卡朋片《药品注册证书》。本品可作为标准药物左旋多巴/苄丝肼或左旋多巴/卡比多巴的辅助用药，用于治疗以上药物不能控制的帕金森病及剂末现象(症状波动)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新华制药(000756.SZ)获恩他卡朋片药品注册证","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000756","BK0239","BK0164"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190496711","title":"新华制药沙格列汀与盐酸二甲双胍缓释片获批药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1190496711","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190496711?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:31","pubTimestamp":1772613076,"startTime":"0","endTime":"0","summary":"新华制药（股票代码：000756）宣布，其研发的沙格列汀与盐酸二甲双胍缓释片正式获得国家药品监督管理局颁发的药品注册证书。该药物主要用于2型糖尿病患者的血糖控制，结合了DPP-4抑制剂与双胍类药物的协同降糖机制。\n此次获批标志着公司在内分泌代谢疾病治疗领域取得重要突破。缓释剂型可减少患者服药频率，提升用药依从性，为糖尿病治疗提供更优选择。随着国内糖尿病患病率持续上升，该产品有望进一步丰富新华制药的代谢类药品管线，增强市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0164","000756"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776409642042,"stockEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":-0.0359},{"period":"3month","weight":-0.0928},{"period":"6month","weight":-0.0729},{"period":"1year","weight":0.0682},{"period":"ytd","weight":-0.0422}],"compareEarnings":[{"period":"1week","weight":0.0225},{"period":"1month","weight":0.0014},{"period":"3month","weight":-0.0113},{"period":"6month","weight":0.0562},{"period":"1year","weight":0.238},{"period":"ytd","weight":0.0218}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东新华制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"76941人(较上一季度减少0.71%)","perCapita":"6484股","listingDate":"1997-08-06","address":"山东省淄博市张店区高新技术产业开发区化工区","registeredCapital":"69668万元","survey":" 山东新华制药股份有限公司的主营业务是开发、制造和销售化学原料药、制剂及化工产品。公司的主要产品是解热镇痛类等原料药、片剂、针剂、胶囊剂等制剂、医药中间体及其他。","listedPrice":3.45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新华制药,000756,新华制药股票,新华制药股票老虎,新华制药股票老虎国际,新华制药行情,新华制药股票行情,新华制药股价,新华制药股市,新华制药股票价格,新华制药股票交易,新华制药股票购买,新华制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}